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Abstract
Background: Studies of antiretroviral therapy (ART) programs in Africa have shown high initial
mortality. Factors contributing to this high mortality are poorly described. The aim of the present
study was to assess mortality and to identify predictors of mortality in HIV-infected patients
starting ART in a rural hospital in Tanzania.
Methods: This was a cohort study of 320 treatment-naïve adults who started ART between
October 2003 and November 2006. Reliable CD4 cell counts were not available, thus ART
initiation was based on clinical criteria in accordance with WHO and Tanzanian guidelines. Kaplan-
Meier models were used to estimate mortality and Cox proportional hazards models to identify
predictors of mortality.
Results: Patients were followed for a median of 10.9 months (IQR 2.9–19.5). Overall, 95 patients
died, among whom 59 died within 3 months of starting ART. Estimated mortality was 19.2, 29.0
and 40.7% at 3, 12 and 36 months, respectively. Independent predictors of mortality were severe
anemia (hemoglobin <8 g/dL; adjusted hazard ratio [AHR] 9.20; 95% CI 2.05–41.3), moderate
anemia (hemoglobin 8–9.9 g/dL; AHR 7.50; 95% CI 1.77–31.9), thrombocytopenia (platelet count
<150 × 109/L; AHR 2.30; 95% CI 1.33–3.99) and severe malnutrition (body mass index <16 kg/m2;
AHR 2.12; 95% CI 1.06–4.24). Estimated one year mortality was 55.2% in patients with severe
anemia, compared to 3.7% in patients without anemia (P < 0.001).
Conclusion: Mortality was found to be high, with the majority of deaths occurring within 3
months of starting ART. Anemia, thrombocytopenia and severe malnutrition were strong
independent predictors of mortality. A prognostic model based on hemoglobin level appears to be
a useful tool for initial risk assessment in resource-limited settings.
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Background
The introduction of highly active antiretroviral therapy in
1996 dramatically improved the prognosis for HIV-
infected patients in the industrialized world [1,2]. Until
recently, however, access to treatment has been severely
limited in developing countries, where the majority of
people with HIV/AIDS live [3]. In 2002, the World Health
Organization (WHO) issued guidelines for scaling up
antiretroviral therapy (ART) in resource-limited settings,
followed by revisions in 2003 and 2006 advocating earlier
initiation of treatment [4-6]. By December 2006, two mil-
lion people in low- and middle-income countries were
receiving ART, but this was still only 28% of those esti-
mated to be in urgent need of it [7].
Few studies have examined the effect of ART in rural
Africa, and experiences from Europe and North America
are not necessarily applicable to such settings. However,
early reports from ART programs in resource-limited set-
tings have been promising, with virological efficacy com-
parable to industrialized countries [3]. Nevertheless,
mortality has been high, particularly the first months after
initiating ART [8-15], and factors contributing to this high
mortality are poorly understood.
A better knowledge of prognostic factors would allow
closer follow-up and more targeted interventions in high-
risk patients, thus reducing excess mortality. The aim of
the present study was to assess mortality and to identify
predictors of mortality in HIV-infected patients starting
ART in a rural African hospital.
Methods
Study setting and participants
Tanzania is a low-income country in East Africa with 38.3
million inhabitants and estimated adult HIV prevalence at
6.5% [7]. Life expectancy at birth is 46.5 years, which is
estimated to be ten years lower than it would have been
without the HIV epidemic [16]. Haydom Lutheran Hospi-
tal is a 400-bed hospital in Manyara region owned by the
Evangelical Lutheran Church of Tanzania. It is the main
health care provider to a rural population of about 260
000 people, and available services include a modern radi-
ology department with ultrasonography and computer
tomography, a fairly well equipped laboratory with
microscopy, bacteriology and biochemistry, as well as
standard surgical and obstetrical services. According to a
recent population-based survey, adult HIV prevalence in
the area is 1.8% [17]. In 2002, the hospital launched a
comprehensive HIV prevention and intervention program
with emphasis on voluntary counseling and testing (VCT)
through outreach services and antenatal clinics. An HIV
Care and Treatment Centre was established adjacent to
the hospital, and from October 2003 ART was provided
free of charge to eligible HIV-infected patients. Most of the
patients enrolled were detected through VCT services in
the villages or were hospitalized patients tested on clinical
suspicion. Clinical officers, under supervision of a physi-
cian, were responsible for medical follow-up of patients.
On-site training was provided by HIV specialists from col-
laborating institutions in Norway. All patients received
pre-treatment counselling, and peer-support groups were
set up in the major villages. A community home-based
care network was established to follow-up adherence and
trace missing patients.
Patients were considered eligible for ART if they were in
WHO stage IV irrespective of CD4 cell count, WHO stage
III with CD4 ≤ 350 cells/μL, or had CD4 ≤ 200 cells/μL
regardless of clinical stage, in accordance with WHO and
Tanzanian guidelines [5,18]. However, since CD4 cell
counts measured by manual techniques were observed to
be unreliable, ART initiation was based solely on clinical
criteria (WHO stage III and IV) in most patients. In addi-
tion, ART was offered to HIV-infected pregnant and lactat-
ing women to prevent vertical transmission.
The present study is a prospective, observational cohort
study of treatment-naïve patients aged 15 years or older
who started ART in Haydom Lutheran Hospital between
October 3, 2003, and November 5, 2006. Women who
were pregnant at the time of ART initiation were excluded
from the study, as were lactating mothers in WHO stage I
or II, who started ART exclusively to prevent vertical trans-
mission. Follow-up data was collected through May 5,
2007. Patients gave written consent to participate in the
study. Ethical approval was obtained from the Medical
Research Coordinating Committee of the National Insti-
tute for Medical Research in Tanzania and Regional Com-
mittee for Medical Research Ethics in Norway.
Treatment, monitoring and endpoints
First-line treatment comprised stavudine (d4T) or zidovu-
dine (ZDV), combined with lamivudine (3TC), and either
nevirapine (NVP) or efavirenz (EFV). Regimen choice was
subject to availability, with use of a generic fixed-dose
combination of d4T, 3TC and NVP whenever possible.
Second-line treatment in case of treatment failure was not
available until December 2006. Patients with CD4 ≤ 200
cells/μL or WHO stage III or IV disease were given co-tri-
moxazole prophylaxis 960 mg thrice weekly or 480 mg
daily. After the initial 2 weeks of daily drug administra-
tion, antiretroviral drugs were dispensed on a monthly
basis.
A standardized form was used for the baseline evaluation,
which included socio-demographic information, medical
history, physical examination, and laboratory investiga-
tions. Clinical staging was performed using the 2003 revi-
sion of the WHO clinical staging system [5]. RoutineBMC Infectious Diseases 2008, 8:52 http://www.biomedcentral.com/1471-2334/8/52
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clinical follow-up was scheduled every 3 months. HIV
infection was established using 2 different rapid antibody
tests. Standard hematology was measured using Sysmex
KX-21 Hematology Analyzer (Sysmex Corp., Kobe,
Japan).
The most recent laboratory results before starting ART
were generally used as baseline values. In a minority of
patients who lacked pre-treatment laboratory tests, how-
ever, results obtained within one month of ART initiation
were used. If two values were obtained within a month,
the mean was employed. Body mass index (BMI, weight in
kilograms divided by height in meters squared) was used
to assess nutritional status. Body weight was measured at
each clinic visit using the same manual scale, and height
was measured using a stadiometer mounted on the scale.
Established cutoff values for BMI were used [19]: normal
(BMI ≥ 18.5 kg/m2), mild malnutrition (BMI 17–18.4 kg/
m2), moderate malnutrition (BMI 16–16.9 kg/m2), and
severe malnutrition (BMI < 16 kg/m2). Anemia was
defined as a hemoglobin level of <12 g/dL for women and
<13 g/dL for men [20], and was classified as mild (hemo-
globin 10–11.9 g/dL for women and 10–12.9 g/dL for
men), moderate (hemoglobin 8–9.9 g/dL) or severe
(hemoglobin < 8 g/dL). Lymphopenia was defined as a
total lymphocyte count (TLC) of <1.2 × 109/L [4], and we
employed an additional cutpoint at 0.6 × 109/L to assess
severe lymphopenia. Thrombocytopenia was defined as
platelet count <150 × 109/L [21].
The main endpoint in our study was death from all causes.
Deaths were registered from hospital records or reported
through home visitors. Other outcomes were also
recorded, including patients who self-stopped treatment,
were transferred to another health facility or were lost to
follow-up. Patients who missed appointments for more
than 3 months and could not be traced by the home visi-
tor, were regarded lost to follow-up.
Statistical analysis
Patients were excluded from the study if sex, age or WHO
stage was not recorded. Date of death was registered by
home visitors; however, in 7 patients with only month
and year recorded we used the 1st of that month, and in 2
patients with unknown death date we used the last follow-
up visit. For subjects who self-stopped treatment, were
transferred out or were lost to follow-up, the date of their
last follow-up visit was used as the censoring date. Finally,
individuals alive and on ART were censored at May 5,
2007.
Kaplan-Meier models were used to estimate survival after
ART initiation, and log rank tests to compare survival
curves. Cox proportional hazards models were used to
identify independent predictors of mortality and calculate
hazard ratios. Multicollinearity was excluded using Spear-
man's correlation coefficient with a cutoff at 0.7. We per-
formed univariable Cox regression analysis for the
following baseline variables: sex, age, tribe, religion, edu-
cation level, ART start year, WHO stage, BMI, hemo-
globin, TLC, platelet count, hepatitis B, syphilis and active
tuberculosis (TB). CD4 cell counts were omitted since the
results were observed to be inaccurate. Baseline variables
significant at P < 0.05 level in univariable analysis were
included in the final multivariable model. We used SPSS
version 14.0 software (SPSS Inc., Chicago, IL, USA) to
analyze the data. All tests were two-sided and level of sig-
nificance was set at P < 0.05.
Results
Baseline characteristics
Of 779 patients enrolled into HIV care between October
3, 2003, and November 5, 2006, 320 treatment-naïve
non-pregnant adults who started ART were included in
the present study. The cohort profile is presented in figure
1. Among 334 adults who had not started ART at censor-
ing, 123 (36.8%) were lost to follow-up, 90 (26.9%) did
not meet clinical criteria for starting ART, 56 (16.8%) died
before ART initiation, 27 (8.1%) were transferred to
another health facility, and the remaining 38 (11.4%)
were still waiting to start treatment.
Patients on ART were followed for a median of 10.9
months (interquartile range 2.9–19.6). Summary statis-
tics of baseline characteristics are given in table 1. Of the
320 patients included, 223 (69.7%) were women and
median age was 35 years (interquartile range 30–43).
There were 104 patients (32.5%) who started ART in the
initial years 2003–04, 117 (36.6%) started in 2005, and
99 (30.9%) in 2006. Initial ART regimen was d4T/3TC/
NVP in 168 patients (52.5%), d4T/3TC/EFV in 58
(18.1%), ZDV/3TC/NVP in 53 (16.6%), ZDV/3TC/EFV in
24 (7.5%), ZDV/3TC/tenofovir in one (0.3%) and miss-
ing in 15 patients (4.7%). Seventy-three patients received
anti-TB treatment at inclusion or started after inclusion.
Mean BMI was 17.6 kg/m2 (standard deviation [SD] 3.1),
mean hemoglobin 10.1 g/dL (SD 2.1), mean TLC 1.4 ×
109/L (SD 0.8) and mean platelet count 266 × 109/L (SD
131).
At ART initiation, 210 patients (65.6%) had clinical AIDS
(WHO stage IV). For comparison, 401 (51.5%) of 779
had clinical AIDS at enrollment into the HIV program.
The most common WHO stage IV conditions among
patients who started ART were: wasting syndrome
(89.0%), oesophageal candidiasis (13.3%), extrapulmo-
nary TB (5.2%) and Kaposi's sarcoma (4.8%).BMC Infectious Diseases 2008, 8:52 http://www.biomedcentral.com/1471-2334/8/52
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Survival analysis
Overall, 95 patients (29.7%) died during the follow-up
period, among whom 59 died within 3 months of starting
ART. Thirty-five patients (10.9%) were transferred to
another health facility, 31 (9.7%) were lost to follow-up
and 7 (2.2%) self-stopped treatment. Estimated mortality
was 19.2, 24.5, 29.0, 35.2 and 40.7% at 3, 6, 12, 24 and
36 months, respectively.
In univariable analysis male sex, ART start year, WHO
stage IV, severe malnutrition, anemia, lymphopenia and
thrombocytopenia were all associated with progression to
death. No such associations were found for age, tribe, reli-
gion, education level, hepatitis B, syphilis or active TB. As
described in table 1, certain baseline values were missing
in 29 patients; hence, there were 291 patients in the final
Cox model. In multivariable analysis significant predic-
tors of mortality were severe and moderate anemia,
thrombocytopenia and severe malnutrition (Table 2). The
hazard of death was significantly reduced in those starting
ART in calendar year 2006 compared with the initial
period 2003–04.
Mortality increased with decreasing hemoglobin. Esti-
mated one year mortality was 3.7% in patients without
anemia, 20.0% in mild anemia, 37.6% in moderate ane-
mia and 55.2% in severe anemia (log rank test, P < 0.001,
Figure 2). The majority of deaths occurred early, and the
corresponding 3 months mortality was 3.7, 8.1, 26.9 and
40.4%, respectively (log rank test, P < 0.001). A similar
trend was observed with decreasing BMI. Estimated one
year mortality was 13.7% in patients with normal nutri-
tional status, 21.0% in mild to moderate malnutrition,
and 46.8% in severe malnutrition (log rank test, P  <
0.001, Figure 3).
Discussion
Mortality was high in this cohort, and most of the deaths
occurred within 3 months of starting ART. Severe and
moderate anemia, thrombocytopenia and severe malnu-
trition were found to be independent predictors of mor-
Profile of the study cohort, Haydom Lutheran Hospital, Tanzania (October 2003–November 2006) Figure 1
Profile of the study cohort, Haydom Lutheran Hospital, Tanzania (October 2003–November 2006).
779 individuals in 
HIV care
703 ART-naive 
HIV-infected adults
334 not on ART
46 pregnant or PMTCT
3 with incomplete data
58 children <15 years
18 ART-experienced
320 adults who 
started ART before 
November 5, 2006, 
were included in the 
studyBMC Infectious Diseases 2008, 8:52 http://www.biomedcentral.com/1471-2334/8/52
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tality. The high early mortality observed in our study is in
line with other similar studies from resource-limited set-
tings [8-15]. Causes of death were not investigated in the
present study; however, in a study from South Africa wast-
ing syndrome, TB, acute bacterial infections, malignancies
and immune reconstitution disease were the major causes
of death [14]. In our cohort more than half of the patients
had clinical AIDS at enrollment into HIV care, and other
African ART programs have also reported high rates of
advanced disease [8-12,14,15]. Stigma and delay in seek-
ing health care, lack of voluntary testing and counseling
services, and health system delays in referral and ART ini-
tiation are possible explanations. Thus, priority must be
given to identify HIV-infected individuals and start treat-
ment earlier in the course of their illness, before they
develop severe opportunistic infections.
Anemia was a strong predictor of mortality in our study.
Patients with severe anemia had nearly 15 times higher
risk of dying during the first year on ART compared to
those with a normal hemoglobin level. Several studies
from Europe and North America have shown that anemia
is an independent predictor of mortality in patients on
ART, even after controlling for CD4 cell count and viral
load [22-24]. Recently, studies from developing countries
have found the same association [9,13]. Indeed, in the
largest African cohort study published to date, severe ane-
mia (hemoglobin <8 g/dL) was the strongest independent
predictor of mortality in 16 198 patients receiving ART in
Zambia [13].
It is uncertain whether the association between anemia
and mortality is causal or whether anemia is rather a
marker of progressive HIV disease. It is known that the
incidence of anemia increases with progression of HIV
infection [23]. Furthermore, anemia can be a feature of
certain opportunistic diseases, like disseminated myco-
bacterial infection and parvovirus B19 [25]. Several other
etiologic factors may be involved in the development of
HIV-associated anemia, including micronutrient deficien-
cies, immunological myelosuppression, impaired eryth-
ropoietin production and blood loss from intestinal
opportunistic disease [25]. The role of iron supplementa-
tion is controversial, as some reports have suggested
adverse effects of iron excess in HIV-infected individuals
in industrialized countries [26,27]. On the contrary,
Table 1: Baseline characteristics and associated mortality among 320 HIV-infected patients starting ART in Tanzania
Characteristic Number of patients Number of Deaths
Age (years)
15–24 26 7 (26.9%)
25–34 129 39 (30.2%)
35–44 95 30 (31.6%)
≥ 45 70 19 (27.1%)
Sex
Male 97 38 (39.2%)
Female 223 57 (25.6%)
Clinical stage
WHO stage I–II 12 1 (8.3%)
WHO stage III 98 18 (18.4%)
WHO stage IV 210 76 (36.2%)
BMI (kg/m2)a
<16 98 46 (46.9%)
16–18.4 105 23 (21.9%)
≥ 18.5 93 14 (15.1%)
Hemoglobin (g/dL)b
<8 49 27 (55.1%)
8–9.9 108 43 (39.8%)
10–11.9 (10–12.9 for men) 104 21 (20.2%)
≥ 12 (≥ 13 for men) 55 2 (3.6%)
TLC (× 109/L)c
<0.6 30 18 (60.0%)
0.6–1.1 116 32 (27.6%)
≥ 1.2 166 42 (25.3%)
Platelet count (× 109/L)d
<150 52 24 (46.2%)
≥ 150 261 66 (25.3%)
a24 values missing (n = 296). b4 values missing (n = 316). c8 values missing (n = 312). d7 values missing (n = 313).
WHO, World Health Organization; BMI, body mass index; TLC, total lymphocyte count.BMC Infectious Diseases 2008, 8:52 http://www.biomedcentral.com/1471-2334/8/52
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recovery from anemia after erythropoietin treatment has
been associated with improved survival [23,24], but high
costs limit its use in poor countries. More recently, ART
has been shown to significantly reduce HIV-associated
anemia in developed countries [28,29]; however, this has
not yet been investigated in rural Africa. Further studies
are needed to explore possible interventions against HIV-
associated anemia in resource-limited settings, including
the role of iron supplementation.
Malnutrition was another strong, independent predictor
of mortality in our study. Estimated one year mortality
was nearly 50% among patients with severe malnutrition.
Previously, studies from industrialized countries have
shown that malnutrition in HIV infection is associated
with morbidity and mortality, even after the introduction
of highly active antiretroviral therapy in the late 1990s
[30-32]. More recently, studies from developing countries
have found that malnutrition is an independent predictor
of mortality in patients starting ART [8,12,13,33]. How-
ever, it is not clear whether targeted therapy for malnutri-
tion will result in improved survival [34]. Studies of
nutritional interventions in HIV patients are urgently
needed in developing countries, where malnutrition is
often a result of poverty and food insecurity.
We found a reduced risk of death in patients starting ART
in later calendar years compared with the initial period
2003–04. A possible explanation is that many patients
with severe AIDS were included in the initial period, as
this was the first clinic to offer ART in the area. However,
since the risk reduction persisted after controlling for clin-
ical stage, we believe that it may also be attributed to
improved skills among local staff managing HIV patients.
The decline in mortality over time supports our experi-
ence that non-physician clinicians can be trained to fol-
low-up and treat HIV-infected patients.
To our knowledge, thrombocytopenia has never previ-
ously been shown to predict mortality in African patients
on ART, although a few studies from North America have
described an increased risk of disease progression and
death [35,36]. Further research is needed to confirm our
findings. WHO stage IV was not significantly associated
with mortality in our study, in contrast to previous reports
[1,8,11-14]. However, the comparison group was almost
entirely composed of WHO stage III patients, which
would weaken the statistical effect of WHO stage IV on
mortality. Furthermore, the accuracy of clinical staging is
probably quite variable in rural Africa. It is interesting that
simple and more objective indicators identified in the
present study appear to have a better predictive ability
than clinical stage.
A prognostic model based on hemoglobin level had a
strong predictive power in our study, separating the
patients into low, low intermediate, high intermediate
and high risk groups (Figure 2). Previously, similar sur-
vival curves for hemoglobin levels have been reported in
European HIV patients, although anemia occurred less
frequently [22]. Hemoglobin is a simple and inexpensive
laboratory test, which can be performed even in rural,
Table 2: Hazard ratios of mortality according to baseline variables in HIV-infected patients starting ART in Tanzania
Unadjusted Adjusteda
Baseline variables HR (95% CI) P HR (95% CI) P
Gender (male vs. female) 1.73 (1.15–2.61) 0.009 1.60 (1.00–2.57) 0.053
WHO stage (IV vs. I–III) 2.71 (1.64–4.49) <0.001 1.46 (0.81–2.65) 0.210
ART start year (vs. 2003–04)
2005 0.55 (0.35–0.87) 0.010 0.64 (0.38–1.08) 0.091
2006 0.30 (0.17–0.56) <0.001 0.40 (0.19–0.83) 0.014
BMI (vs. ≥ 18.5 kg/m2)
<16 4.17 (2.29–7.60) <0.001 2.12 (1.06–4.24) 0.034
16–18.4 1.60 (0.82–3.10) 0.168 1.27 (0.62–2.61) 0.516
Hemoglobin (vs. ≥ 12 g/dL for women and ≥ 13 for men)
<8 22.7 (5.40–95.7) <0.001 9.20 (2.05–41.3) 0.004
8–9.9 13.5 (3.28–55.9) <0.001 7.50 (1.77–31.9) 0.006
10–11.9 (10–12.9 for men) 6.21 (1.46–26.5) 0.014 4.03 (0.93–17.5) 0.063
TLC (vs. ≥ 1.2 × 109/L)
<0.6 3.58 (2.05–6.24) <0.001 1.72 (0.87–3.39) 0.117
0.6–1.1 1.10 (0.69–1.74) 0.699 0.79 (0.48–1.32) 0.371
Platelet count (<150 vs. ≥ 150 × 109/L) 2.23 (1.40–3.57) 0.001 2.30 (1.33–3.99) 0.003
aCox proportional hazards model adjusted for all variables listed in the table.
HR, hazard ratio; CI, confidence interval; ART, antiretroviral therapy; WHO, World Health Organization; BMI, body mass index; TLC, total 
lymphocyte count.BMC Infectious Diseases 2008, 8:52 http://www.biomedcentral.com/1471-2334/8/52
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basic clinics. We believe it can be used as a simple and
practical tool for initial risk assessment in the absence of
CD4 cell count and viral load. Such early prognostic infor-
mation would allow a more targeted search for opportun-
istic infections and closer follow-up in high-risk
individuals, thus reducing excess mortality. Although the
exact mortality figures from the present study can not nec-
essarily be applied to other populations, we believe the
concept of using hemoglobin level to identify patients
with a poor prognosis can be used elsewhere. This simple
prognostic model should be tested out in other African
settings to assess its generalizability.
There are some weaknesses of our study. First, mortality
might be underestimated, since patients lost to follow-up
probably include individuals dying at home without
being reported. Although the proportion of patients lost
to follow-up in the present study (9.7%) was comparable
to other African studies [12,13], data quality would be
improved with better cohort retention. Second, the results
might be affected by selection bias towards patients with
more severe disease, since the study was conducted in a
hospital setting. Third, some patients measured baseline
hemoglobin shortly after ART initiation, which might
have led to an overestimation of the prevalence of anemia
in patients with a ZDV-based regimen. However, post-ART
hemoglobin was only employed in a small number of
patients, and it is unlikely that this has introduced any sys-
tematic bias into the study. Fourth, it is known that the
generalizability of a prognostic system can be impaired if
important independent predictors are left out [37]. We
lacked reliable CD4 cell counts and viral loads, which are
established predictors of morbidity and mortality in
patients on ART [1]. However, our results strongly suggest
that simple and available measurements can be useful
alternative prognostic markers.
The main strength of our study is that it was carried out in
a rural African hospital with use of national staff and
inclusion of all eligible patients. Most other African ART
Kaplan-Meier survival curves according to baseline hemoglobin Figure 2
Kaplan-Meier survival curves according to baseline hemoglobin. Normal: >12 g/dL (>13 g/dL for men); mild anemia: 
10–11.9 g/dL (10–12.9 g/dL for men); moderate anemia: 8–9.9 g/dL; severe anemia: <8 g/dL.BMC Infectious Diseases 2008, 8:52 http://www.biomedcentral.com/1471-2334/8/52
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studies have been performed in urban areas [9-11,13-15],
in research settings with strict inclusion and exclusion cri-
teria [38], or with support from an international non-gov-
ernmental organization [8,10,12]. We believe that our
results better reflect the reality in a rural hospital in sub-
Saharan Africa, and thus may be applicable to other simi-
lar settings.
Conclusion
We found high mortality among patients starting ART in
this rural Tanzanian hospital, with the majority of deaths
occurring within 3 months of ART initiation. Many
patients enrolled with advanced immunodeficiency, and
priority should be given to identify HIV-infected individ-
uals and start ART earlier in the course of their illness.
Anemia, thrombocytopenia and severe malnutrition were
strong independent predictors of mortality. A simple
prognostic model based on hemoglobin level appears to
be a useful tool for initial risk assessment in resource-lim-
ited settings.
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